Effect of the angiotensin II receptor antagonist irbesartan on insulin sensitivity and metabolic profile in patients with chronic heart failure

Trial Profile

Effect of the angiotensin II receptor antagonist irbesartan on insulin sensitivity and metabolic profile in patients with chronic heart failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs Irbesartan (Primary)
  • Indications Chronic heart failure
  • Focus Biomarker; Pharmacodynamics
  • Acronyms IRIS-HF
  • Most Recent Events

    • 31 Mar 2009 Results were presented at the 58th Annual Scientific Session of the American College of Cardiology (ACC-2009).
    • 30 Aug 2008 Results were presented at ESC Congress 2008: Annual Congress of the European Society of Cardiology.
    • 30 Oct 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top